Next Article in Journal
Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma
Next Article in Special Issue
Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype
Previous Article in Journal
Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins
Previous Article in Special Issue
Bone and Soft Tissue Sarcoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 6
10.3390/cancers13061202
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Current Status of Management and Outcome for Patients with Ewing Sarcoma

Cancers 2021, 13(6), 1202; https://doi.org/10.3390/cancers13061202
by Asle Charles Hesla *, Andri Papakonstantinou and Panagiotis Tsagkozis
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2021, 13(6), 1202; https://doi.org/10.3390/cancers13061202
Submission received: 18 January 2021 / Revised: 26 February 2021 / Accepted: 27 February 2021 / Published: 10 March 2021
(This article belongs to the Special Issue Bone and Soft Tissue Sarcoma)

Round 1

Reviewer 1 Report

The authors well discuss  the topic,they center the principal argument regarding  Ewing Sarcoma . they make a detailed analysis of both therapies and diagnostic evaluations. I would just have a suggestion. Some  authors recently evaluated the beta 3 adrenergic receptor as a possible additional marker in Ewing's sarcoma. I would suggest that the authors consider this topic in the biomolecular section.

I suggest that the work should be accepted with minor revisions

Author Response

Dear Reviewer,

We thank you for your very useful comment.

Reply to comment: We have now added a paragraph discussing the possible role of the β3-adrenergic receptor as a prognostic marker in line 141 to 146 under the "Molecular diagnostics" section. 

Kind regards

Asle Hesla

Reviewer 2 Report

Overall, this review is well written and focused on the treatment of Ewing sarcoma. I only have a few comments and listed as below:

I encourage the authors to discuss Ewing sarcoma's intratumor heterogeneity because this phenotype may be linked with current treatment resistance. A better understanding of the mechanisms may help develop personalized therapy or precision medicine.

The authors mentioned immunotherapy in the conclusion part. I suggest that the authors discuss how immunotherapy could be a potential treatment method or combination therapy with other agents.

Table 1, why the mTOR inhibitor clinical trial only showed one patient?

Author Response

Dear Reviewer,

We thank you for your valuable comments.

Reply to comment #1: We have now added 2 paragraphs on intratumoral heterogeneity under the section "Molecular diagnostics", line 147 to 172.

Comment # 2: We have now added paragraphs on immunotherapy under the section "Novel systemic treatments" line 260 to 272.

Comment #3:  The reference regards the "phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors", that was presented as poster at ASCO 2020 Virtual (first auhor Filemon Dela Cruz). Among the 17 patients included, only one had Ewing sarcoma diagnosis and was treated with the escalated lenvatinib dose (11mg/m2) and everolimus 3 mg/m2.

Kind regards

Asle Hesla

Author Response File: Author Response.docx

Back to TopTop